Stock Research for VSTM


Featured Broker: Ally Invest

Get the due diligence for another stock.


VSTM Stock Chart & Research Data

The VSTM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VSTM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


VSTM Due diligence Resources & Stock Charts

The VSTM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View VSTM Detailed Price Forecast - CNN Money CNN View VSTM Detailed Summary - Google Finance
Yahoo View VSTM Detailed Summary - Yahoo! Finance Zacks View VSTM Stock Research & Analysis -

Stock Analysis

TradeIdeas View VSTM Trends & Analysis - Trade-Ideas Barrons View VSTM Major Holders - Barrons
NASDAQ View VSTM Call Transcripts - NASDAQ Seeking View VSTM Breaking News & Analysis - Seeking Alpha
Spotlight View VSTM Annual Report - OTC Report View VSTM OTC Short Report -
TradeKing View VSTM Fundamentals - TradeKing Charts View VSTM SEC Filings - Bar Chart
WSJ View Historical Prices for VSTM - The WSJ Morningstar View Performance/Total Return for VSTM - Morningstar
MarketWatch View the Analyst Estimates for VSTM - MarketWatch CNBC View the Earnings History for VSTM - CNBC
StockMarketWatch View the VSTM Earnings - StockMarketWatch MacroAxis View VSTM Buy or Sell Recommendations - MacroAxis
Bullish View the VSTM Bullish Patterns - American Bulls Short Pains View VSTM Short Pain Metrics -

Social Media Mentions

StockTwits View VSTM Stock Mentions - StockTwits PennyStocks View VSTM Stock Mentions - PennyStockTweets
Twitter View VSTM Stock Mentions - Twitter Invest Hub View VSTM Investment Forum News - Investor Hub
Yahoo View VSTM Stock Mentions - Yahoo! Message Board Seeking Alpha View VSTM Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for VSTM - Insider Cow View Insider Transactions for VSTM - Insider Cow
CNBC View VSTM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for VSTM - OTC Markets
Yahoo View Insider Transactions for VSTM - Yahoo! Finance NASDAQ View Institutional Holdings for VSTM - NASDAQ

Stock Charts

FinViz View VSTM Stock Insight & Charts - StockCharts View VSTM Investment Charts -
BarChart View VSTM Stock Overview & Charts - BarChart Trading View View VSTM User Generated Charts - Trading View

Latest Financial News for VSTM

Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?
Posted on Tuesday September 18, 2018

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

Analysts Are Bullish on Verastem in September
Posted on Wednesday September 12, 2018

On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.

This Cancer Stock is up Over 3900%
Posted on Thursday September 06, 2018

HENDERSON, NV / ACCESSWIRE / September 7, 2018 / A fascinating biotech firm we discovered PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in the last ten trading session going from a low of $0.0039 ...

Verastem Oncology Announces Investigator Sponsored Study on Duvelisib in Combination with Venetoclax
Posted on Thursday September 06, 2018

Verastem, Inc. (VSTM), operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Stock Market & Investing Books

Enter a stock symbol to view the stock details.